THNR's Weight-Loss Index Swaps Hims & Hers for Gilead

Thematic Investing Content Hub THNR’s Weight-Loss Index Swaps Hims & Hers for Gilead DJ Shaw September 21, 2026 The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug & Treatment Index (THINR), completed a scheduled rebalance on Sept. 18. Key Takeaways: THNR’s index dropped Scholar Rock and Hims & Hers for Gilead Sciences and Structure Therapeutics on Sept. 18. The fund’s net asset value climbed 5.9% year to date while its benchmark returned 6.5% through August. Roche, AstraZeneca and Eli Lilly advanced competing weight-loss treatments this year, from muscle-sparing shots to oral pills. VettaFi’s rebalance added Gilead Sciences, Inc. (GILD) and Structure Therapeutics Inc. (GPCR) , while dropping Scholar Rock Holding Corp. (SRRK) and Hims & Hers Health, Inc. (HIMS) . See more: Taking Fan Passion to the Market: Amplify Files for Sports Ownership ETF Drugmakers are moving past weekly GLP-1 shots toward oral pills, monthly dosing and muscle-sparing treatments. Morgan Stanley expects the weight-loss drug market to grow from $15 billion in 2024 to $150 billion by 2035, according to research cited on Amplify’s website. Established drugmakers drove most of the index’s gains before the reshuffle. Merck & Co., Inc. (MRK) gained 42.4% and Innovent Biologics, Inc. (1801:HKG) gained 25.7% year to date, the index’s two largest contributors, according to VettaFi. Hims & Hers Health lost nearly half its value over the same span and was cut loose. THNR held about $5.8 million in net assets as of Sept. 18, Amplify’s data shows. Its net asset value has gained 5.9% year to date through August and 17.9% over the past year. The index returned 6.5% over the same year-to-date stretch. Lilly, Roche Chase Next-Gen Weight-Loss Drugs Eli Lilly & Co. (LLY) , the fund’s top holding at nearly 10% of assets, delivered the year’s biggest earnings beat. Second-quarter revenue jumped 48% to $22.97 billion on Mounjaro and Zepbound demand, TradingView reported. Lilly also raised its 2026 revenue forecast to a range of $85 billion to $87 billion. CEO David Ricks told TradingView the company’s future “has never been brighter.” He cited next-generation drug Retatrutide, which Lilly plans to file with the FDA in early 2027. AstraZeneca (AZN) , a 5.4% index weight, moved its oral weight-loss pill elecoglipron into Phase III trials in June. A mid-stage study found an 11.8% weight loss at 36 weeks on its highest dose, versus 0.3% for placebo. AstraZeneca reported the results in a press release. Roche Holding (ROP) , the index’s fourth-largest holding at 5.3%, took a different approach: preserving muscle while patients lose fat. In August, Roche licensed a muscle-sparing weight-loss drug from Hanmi Pharmaceutical Co., according to BioPharma Dive. Roche will pay $190 million upfront and up to $2.3 billion total. Gilead cracked THNR’s 10 largest holdings at 5.2% of assets within days of its debut, Amplify’s holdings data show. Structure Therapeutics settled further down the fund’s 20-stock portfolio, classified under the index’s Phase 3 Drugs category, per VettaFi data. For more news, information, and analysis visit the Thematic Investing Content Hub . RELATED TOPICS Amplify ETFs dj shaw GLP-1 rebalance thematic investing Content Hub weight loss ETF Earn free CE credits and discover new strategies